AngioDynamics Signs Distribution Agreement With HDC Corporation.

Business Editors, Health/Medical Writers

QUEENSBURY, N.Y.--(BW HealthWire)--March 22, 2000

AngioDynamics, Inc., a wholly owned subsidiary of E-Z-EM, Inc. (AMEX: EZM.A and EZM.B), announced today that it has entered into a distribution agreement with HDC Corporation, a leading manufacturer of vascular access products.

The HDC vascular access product line consists of implanted medication ports, central venous catheters and peripherally inserted central catheters (PICC's). These catheter-based products are used to deliver chemotherapeutic agents, antibiotics and total parental feeding solutions into the central circulatory system where they can easily mix with a large volume of blood. Rapidly mixing these drugs in a large volume of blood prevents harm to the vessels. Proper placement of the catheters is important and is a major reason many of these procedures are now being performed by Interventional Radiologists who have both the catheter placement skills and high-resolution fluoroscopy equipment.

Located in the heart of the Silicon Valley, HDC is a privately held corporation that designs and develops medical devices with a focus on vascular access and regional anesthesia. HDC's products, V-Cath(r), Neuro-Trace(r) Chemo-Port(r) and Chemo-Cath(r), are known by medical practitioners worldwide in terms of quality and ease of use. Through years of research the company has developed a core competency in manufacturing silicon rubber based implanted medical devices. HDC has used this expertise to design products specifically for the Interventional Radiologists.

Eamonn P. Hobbs, AngioDynamics President and CEO said: "This strategic alliance with HDC is an important step as our company continues to focus on the needs of our customer, the Interventional Radiologist. It will allow our sales organization to focus on this important procedural need in Interventional Radiology and will free the HDC sales organization to focus on other departments and professionals within the hospital. We have clearly identified vascular access as one of the fastest growing procedures being performed by Interventional Radiologists and believe it may represent nearly 35% of their procedures. The ability to represent HDC's line of high quality vascular access catheters adds yet another critical product line to our product portfolio and complements our recently introduced ABSCESSION(tm) Drainage Catheter, Work*Horse(tm) PTA balloon and VISTAFLEX(tm) biliary stent."

Carey Bolden, HDC's President and CEO said: "This marketing alliance with a strong Interventional Radiology partner, AngioDynamics, marks a milestone in the company's strategy to build corporate alliances for its flagship products. We clearly believe that strong partnerships exist between the IR and other hospital IV professions who have made the V-Cath a symbol of quality vascular access. This move will continue to fuel the growth we are experiencing by turning our sales focus to the IV Professional and Vascular Surgeon as well as expanding our presence with innovative products in Regional Anesthesia."

The statements made in this press release contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the company's expectations. In addition to matters described in this release, future actions by the FDA, results of pending or future clinical trials, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc. including but not limited to its Form 10-Q for the quarter ended February 26, 2000, as well as its Annual Report on Form 10-K, may affect the actual results achieved by the Company.